The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio Inc. CEO and director Jodie Pope Morrison reported an automatic sale of 3,221 shares on October 6, 2026, to cover tax withholding obligations tied to vesting of performance-based restricted stock units; the sale was not at her discretion. The reported weighted-average price was $8.3198 per share, with transactions ranging from $8.08 to $8.32. Her direct holdings after the sale were 340,038 shares. No Rule 10b5-1 plan is reported.
Q32 Bio Inc. (QTTB) Chief Scientific Officer Shelia M. Violette sold 917 shares of common stock on October 6, 2026, at a weighted average price of $8.3197 per share. The shares were required to be sold to cover tax withholding obligations tied to vesting performance-based restricted stock units; the sales were automatic and not at her discretion. Her direct holdings after the sale were 126,854 shares. Violette Holdings LLC held 36,277 shares; Violette is its manager and disclaims beneficial ownership except to the extent of her pecuniary interest, if any.
Q32 Bio Inc.'s CFO and President, Lee Kalowski, sold 1,301 common shares on October 6, 2026, at a weighted average price of $8.3198 per share. The shares were sold in multiple transactions priced from $8.08 to $8.32 to cover tax withholding obligations tied to vesting performance-based restricted stock units; the sales were automatic and not at his discretion. He directly held 137,170 shares after the sale. No Rule 10b5-1 plan is reported.
Q32 Bio Inc. (QTTB) is the issuer in a Schedule 13G reporting shared beneficial ownership by Frazier-affiliated entities. Frazier Life Sciences Public Fund, L.P. directly holds 1,755,116 shares, reported as 5.9%. Frazier Life Sciences XI, L.P. directly holds 23,029 shares (0.1%), and Frazier Life Sciences XII, L.P. directly holds 125,039 shares (0.4%).
The filing identifies general partners and management entities as also reporting these positions through shared voting and dispositive powers; those are overlapping attribution chains, not additional direct holdings. The percentages are based on 29,769,466 Q32 Bio shares outstanding as of August 3, 2026.
Q32 Bio Inc. (symbol: QTTB) is the issuer of record for a Form 8-K filing submitted to the SEC. Q32 Bio Inc. reported additional results from Part B of its SIGNAL-AA Phase 2a trial of bempikibart in severe or very severe alopecia areata. In the 33-patient study, the company described clinically meaningful efficacy on primary and key secondary endpoints at Week 36, with responses maintained and deepened during the 16-week off-drug follow-up.
Q32 Bio described the safety profile as generally well tolerated, with no new safety signals and no serious or Grade 3-or-higher adverse events related to treatment. Injection-site reactions were the most common treatment-emergent adverse event (36.3%); their incidence was 4% across Part B dose administrations. The company plans to advance bempikibart into a registration-directed program in the first half of 2027, subject to planned regulatory discussions in the second half of 2026, and anticipates Part B open-label extension data in the second half of 2027.
Q32 Bio Inc. (QTTB) reported senior leadership changes, appointing José Trevejo, M.D., Ph.D. as Chief Medical Officer and Ellie Hershberger, Pharm.D. as Chief Development Officer. Both bring extensive late-stage clinical and regulatory experience in dermatology, rare diseases, infectious disease and biologics development.
The company describes itself as a clinical-stage biotechnology business developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, led by its anti-IL-7Rα antibody bempikibart (ADX-914), now in a Phase 2 alopecia areata program. Q32 Bio states plans to advance bempikibart into a registration-directed program for severe or very severe alopecia areata in the first half of 2027 and to explore additional alopecia areata populations and other autoimmune indications, while emphasizing that these are forward-looking statements subject to clinical, regulatory and financing risks.
Point72 Asset Management, L.P., Point72 Capital Advisors, Inc. and Steven A. Cohen report beneficial ownership of 1,173,396 shares of Q32 Bio Inc. common stock as of June 30, 2026. This represents 4.95% of 23,681,415 Q32 Bio shares outstanding, including shares issued in a May 26, 2026 private placement.
The reporting persons have no sole voting or dispositive power and instead report shared voting and shared dispositive power over all 1,173,396 shares through an investment fund managed by Point72 Asset Management. They state the filing should not be construed as an admission of beneficial ownership for Section 13 purposes.
Q32 Bio Inc. received an amended Schedule 13G indicating that Sirenia Capital Management LP and Alex Silverstein no longer beneficially own any of the company’s common stock. The filing reports 0 shares beneficially owned, representing 0% of the outstanding common stock, with no sole or shared voting or dispositive power.
Sirenia had previously reported holdings on behalf of investment funds it manages, with Mr. Silverstein as managing member of Sirenia’s general partner. Both parties now report ownership of 5 percent or less of this class.
Q32 Bio Inc. is a clinical stage biotechnology company developing bempikibart, a fully human anti‑IL‑7Rα antibody, for alopecia areata and other autoimmune and inflammatory diseases. It has no approved products and continues to invest heavily in research and development.
For the quarter ended June 30, 2026, the company reported a net loss of $8.9 million, or $0.44 per share, compared with $9.5 million, or $0.78 per share, a year earlier. For the first six months of 2026, the net loss was $16.6 million versus $20.5 million in the prior‑year period.
Cash and cash equivalents were $106.3 million at June 30, 2026, up from $48.3 million at year‑end 2025, driven by a registered direct offering, at‑the‑market sales and a private placement, while venture debt was fully repaid. Subsequent to quarter‑end, a follow‑on public offering added $187.6 million of net proceeds, further strengthening liquidity. Management expects existing cash to fund operations for at least one year, though additional capital will ultimately be required.
Q32 Bio Inc. reported second-quarter 2026 results and progress in its alopecia areata program. In Part B of the Phase 2a SIGNAL-AA trial, bempikibart achieved a 35.3% mean reduction in Severity of Alopecia Tool score in the modified intent-to-treat set; 40.0% of patients reached a SALT-20 response at Week 36 in that set and 30.3% in the full intent-to-treat population, with a generally well-tolerated safety profile. Enrollment and dosing continue in the open-label extension, and a registration-directed program in severe and very severe alopecia areata is planned for the first half of 2027, subject to regulatory discussions in late 2026.
Cash and cash equivalents were $106.3 million as of June 30, 2026, and a July 2026 public offering raised approximately $200.0 million in gross proceeds, which together are expected to fund operations through topline Phase 3 results for the planned registration-directed program. For the quarter, research and development expenses were $4.3 million, general and administrative expenses $4.9 million, and net loss $8.9 million, or $0.44 per share.